Most of the research in cancer economics has been on total cost and cost effectiveness, which is why Veena Shankaran MD, MS, assistant professor in the division of medical oncology at the University of Washington, wanted to have a panel discussion on financial toxicity at the ISPOR 20th Annual Meeting.
Most of the research in cancer economics has been on total cost and cost effectiveness, which is why Veena Shankaran MD, MS, assistant professor in the division of medical oncology at the University of Washington, wanted to have a panel discussion on financial toxicity at the ISPOR 20th Annual Meeting.
The goal of the talk was to present strategies to measure financial burden and how to decrease the financial burden.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More